Ravipati Mamata, Katragadda Srikanth, Swaminathan Paari Dominic, Molnar Janos, Zarling Edwin
VA Medical Center, Toledo, Ohio, USA.
Gastrointest Endosc. 2009 Oct;70(4):658-664.e5. doi: 10.1016/j.gie.2009.02.029. Epub 2009 Jul 29.
Previous clinical trials on the treatment of esophageal variceal bleeding yielded mixed results regarding the efficacy of endoscopic procedures compared with pharmacotherapy only.
To compare the efficacy of endoscopic procedures with that of pharmacotherapy in the prevention of mortality and rebleeding.
A systematic literature review was performed to identify randomized, controlled trials of the efficacy of pharmacotherapy and endoscopic therapy. A meta-analysis was performed by using the Comprehensive MetaAnalysis software package. A 2-sided alpha error <.05 was considered statistically significant (P < .05).
Twenty-five clinical trials with a total of 2159 patients were eligible for meta-analysis.
Relative risk (RR) with 95% confidence interval (CI) was computed for all-cause mortality, mortality from rebleeding, all-cause rebleeding, and rebleeding caused by varices.
Pharmacotherapy was as effective as endoscopic procedures in preventing rebleeding (RR 1.067; 95% CI, 0.865-1.316; P = .546), variceal rebleeding (RR 1.143; 95% CI, 0.791-1.651; P = .476), all-cause mortality (RR 0.997; 95% CI, 0.827-1.202, P = .978), and mortality from rebleeding (RR 1.171; 95% CI, 0.816-1.679; P = .39). Pharmacotherapy combined with endoscopic procedures did not reduce all-cause mortality (RR 0.787; 95% CI, 0.587-1.054; P = .108) or mortality caused by rebleeding (RR 0.786; 95% CI, 0.445-1.387; P = .405) compared with endoscopic procedures. However, combination therapy (endoscopic procedure plus pharmacotherapy) significantly reduced the incidence of all rebleeding (RR 0.623; 95% CI, 0.523-0.741; P < .001) and variceal rebleeding (RR 0.601; 95% CI, 0.440-0.820; P < .001).
Heterogeneity of patient population and different treatment protocols may have affected our meta-analysis.
Pharmacotherapy may be as effective as endoscopic therapy in reducing rebleeding rates and all-cause mortality. Pharmacotherapy plus endoscopic intervention is more effective than endoscopic intervention alone.
以往关于食管静脉曲张破裂出血治疗的临床试验表明,与单纯药物治疗相比,内镜治疗的疗效不一。
比较内镜治疗与药物治疗在预防死亡率和再出血方面的疗效。
进行了一项系统的文献综述,以确定药物治疗和内镜治疗疗效的随机对照试验。使用综合荟萃分析软件包进行荟萃分析。双侧α错误<.05被认为具有统计学意义(P<.05)。
25项临床试验共2159例患者符合荟萃分析条件。
计算全因死亡率、再出血死亡率、全因再出血率和静脉曲张引起的再出血率的相对风险(RR)及95%置信区间(CI)。
在预防再出血(RR 1.067;95%CI,0.865 - 1.316;P =.546)、静脉曲张再出血(RR 1.143;95%CI,0.791 - 1.651;P =.476)、全因死亡率(RR 0.997;95%CI,0.827 - 1.202,P =.978)和再出血死亡率(RR 1.171;95%CI,0.816 - 1.679;P =.39)方面,药物治疗与内镜治疗效果相当。与内镜治疗相比,药物治疗联合内镜治疗并未降低全因死亡率(RR 0.787;95%CI,0.587 - 1.054;P =.108)或再出血导致的死亡率(RR 0.786;95%CI,0.445 - 1.387;P =.405)。然而,联合治疗(内镜治疗加药物治疗)显著降低了所有再出血的发生率(RR 0.623;95%CI,0.523 - 0.741;P<.001)和静脉曲张再出血的发生率(RR 0.601;95%CI,0.440 - 0.820;P<.001)。
患者群体的异质性和不同的治疗方案可能影响了我们的荟萃分析。
在降低再出血率和全因死亡率方面,药物治疗可能与内镜治疗效果相当。药物治疗加内镜干预比单纯内镜干预更有效。